Substance P/Neurokinin-1 Receptor Antagonist international drug patents, pharmaceutical manufacturers and generics

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tersera	VARUBI	rolapitant hydrochloride	TABLET;ORAL	206500-001	Sep 1, 2015		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
Tersera	VARUBI	rolapitant hydrochloride	TABLET;ORAL	206500-001	Sep 1, 2015		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			⤷ Start Trial
Tersera	VARUBI	rolapitant hydrochloride	TABLET;ORAL	206500-001	Sep 1, 2015		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 18, 2026

The Substance P/Neurokinin-1 (NK1) receptor antagonist class is anchored by a small set of marketed assets, with the patent and exclusivity picture dominated by older small-molecule launches and incremental protection around antiemetic regimens, pediatric dosing, and formulations. The highest commercial exposure sits in anticipatory and chemotherapy-induced nausea and vomiting (CINV) and related emetogenic settings, where NK1 antagonists are used in combination regimens with 5-HT3 antagonists and corticosteroids. Across the class, most near-term generic entry risk concentrates on patent estates tied to specific dosing schedules and formulation IP, while method-of-use coverage and follow-on patents shape Paragraph IV viability and settlement leverage.

Which NK1 (Neurokinin-1) receptor antagonists are marketed and what drives their demand?

Featured snippet answer: NK1 antagonists with established commercial use are led by aprepitant, fosaprepitant (prodrug of aprepitant), and rolapitant, used primarily in CINV prevention regimens. Demand is driven by guideline-consistent combination use with 5-HT3 antagonists and corticosteroids, and by formulary placement in oncology infusion centers and outpatient chemo pathways.

Core clinical use and market pull

NK1 receptor antagonists are positioned in:

Highly emetogenic chemotherapy (HEC) CINV prevention, typically as part of multi-drug prophylaxis.
Moderately emetogenic chemotherapy (MEC) regimens when risk warrants.
Breakthrough nausea/vomiting management depends on local practice; NK1 antagonists are usually prophylactic rather than rescue.
Radiation-induced nausea/vomiting (RINV) and other emetogenic settings in subsets of territories, depending on product labeling.

Commercial dynamic: bundling with companion standards

NK1 products tend to be “bundle winners” in formulary ecosystems:

They are pulled into protocols that include 5-HT3 antagonists (e.g., palonosetron, ondansetron) and corticosteroids (e.g., dexamethasone), plus adjuncts when needed.
Substitution risk is reduced when NK1 antagonists are embedded into standard order sets and reimbursement models.

Formulation and route as differentiation

Oral NK1 antagonists support outpatient adherence.
IV options support infusion workflow integration, especially where rapid antiemetic onset is required.

What patents protect aprepitant, fosaprepitant, and rolapitant?

Featured snippet answer: Patent estates for NK1 antagonists typically include (1) composition-of-matter around the small molecule and stereochemistry, (2) prodrug or salt form claims (for fosaprepitant-related structures), (3) formulation patents for specific dosage forms (capsules, tablets, IV solutions), and (4) method-of-use claims covering CINV schedules and combination regimens.

Patent estate components common to the class

Composition of matter (early-life core)
- Small-molecule NK1 antagonists and salts.
Prodrug claims
- For products like fosaprepitant, prodrug structure and interconversion are usually protected.
Formulation and manufacturing
- IV infusion stability, excipient systems, particle properties, and container-closure systems.
Method-of-use and dosing regimen
- Specific CINV day-1/day-2 schedules, including extended coverage windows and combination sets.

How to map estate strength to generic entry risk

Strongest barrier: intact, unexpired method-of-use or schedule-specific patents with clear claim coverage that generics would need to “design around.”
Moderate barrier: formulation patents where generic products can use alternative excipients or different presentation routes.
Lower barrier: patents that only repeat known combinations without specific schedule constraints, or claims that are narrow enough for design-around.

When does NK1 antagonism exclusivity end and what is the generic entry timeline?

Featured snippet answer: Exclusivity timing depends on the specific product and the last-to-expire protection layer, usually combining patent expiry with regulatory exclusivity (where applicable) and lifecycle management. In practical market terms, generic entry tends to follow expiration of the core composition/prodrug estate first, then remains delayed by formulation or dosing regimen patents.

Exclusivity vs patent expiry: what matters in practice

Regulatory exclusivities (application-specific) can delay first generic filings in the background, but federal patent expiry drives the litigation and “workarounds” reality.
Settlement agreements after Paragraph IV filings frequently fix entry dates or volume carve-outs.

Timeline structure used for NK1 class assessments

Core compound expiry: typically sets the earliest theoretical generic entry date.
Extended layers: formulation and method-of-use patents can extend effective market exclusivity even after core expiry.
Lifecycle cadence: new presentations (capsule to tablet switches, IV stability improvements, pediatric label expansions) can create incremental patent filings that affect later entry.

What Orange Book status exists for NK1 receptor antagonists and how does it shape Hatch-Waxman risk?

Featured snippet answer: Orange Book listings for NK1 antagonists typically include multiple drug substance and drug product patents. Hatch-Waxman risk is highest when listed patents include method-of-use or combination regimen patents that directly map to label indications and dosing schedules.

Orange Book listing patterns by claim type

Drug substance and prodrug patents: often block a generic filing until expiry or settlement.
Drug product patents: can protect specific dosage forms and stability or bioavailability characteristics.
Method-of-use patents: create Paragraph IV challenges because generics must certify non-infringement or invalidity relative to each listed patent relevant to the proposed label.

Paragraph IV viability depends on label mapping

For NK1 antagonists, generic viability turns on whether the proposed generic label mirrors the patented regimen:

If claims track label dosing days and combination components, Paragraph IV challengers face higher infringement exposure.
If challengers carve indications or adopt different schedule language, they may reduce claim coverage.

How many NK1 antagonist patents are typically in force and which jurisdictions drive outcomes?

Featured snippet answer: NK1 antagonist estates usually include a multi-patent bundle spanning multiple jurisdictions, but litigation and commercial outcomes are most influenced by US patent coverage and US regulatory labeling because that determines generic launch timing in the largest market.

Jurisdictional hierarchy for commercial launch

United States: primary driver of generic entry because of Hatch-Waxman and Orange Book-based litigation.
Europe: can constrain supply through national injunction risk, but does not deterministically time generic launches in the same way as US.
Other markets: often follow patent coverage with varying enforcement intensity and parallel import rules.

What to measure for “how many patents”

In practice, decision-grade counts track:

number of Orange Book listed patents per active ingredient/product
number of active asserted families in litigation
number of composition vs formulation vs method patents that are both listed and likely mapped to label regimens

Which NK1 antagonist patent disputes have mattered for generic launch dates?

Featured snippet answer: NK1 antagonists have seen multiple Hatch-Waxman challenges where Paragraph IV filings targeted one or more listed patents, followed by settlements that often set delayed entry dates rather than full invalidation.

Litigation mechanics that shape outcomes

First wave: challenges to core compound/prodrug patents.
Second wave: challenges to formulation and method-of-use patents once core patents lapse.
Settlement patterns: entry delayed to a date tied to the last expiring patent, sometimes paired with non-commercial terms or limited launch scopes.

What to look for in filings and settlements

Whether the settlement is tied to last-to-expire US patents.
Whether the generic gets an authorization to launch with a label carve-out.
Whether any party agrees to refrain from launching certain strengths or presentations.

What formulations are protected and how do dosage forms affect IP barriers?

Featured snippet answer: Formulation protection is a major barrier for NK1 antagonists because IV stability, capsule/tablet excipient systems, and specific container-closure configurations can generate enforceable product claims that are difficult for generics to replicate.

Dosage form-specific protection themes

IV NK1 antagonists (prodrug solutions): stability and impurity control, reconstitution/infusion constraints, and container closure integrity.
Oral capsules/tablets: particle size distribution, dissolution profiles, and excipient systems tied to bioavailability.

How generics attack formulation patents

Alternative excipient systems that still meet specifications.
Different manufacturing process parameters to avoid literal infringement.
Patent invalidity arguments premised on known formulation approaches and obviousness.

Do NK1 antagonist method-of-use patents block generic label copying?

Featured snippet answer: Yes, method-of-use patents can block generic label copying when claims cover specific antiemetic schedules and combination regimens that match the approved labeling. When method patents remain unexpired, generics can face injunction risk or must negotiate settlements.

Common method-of-use claim structures

CINV prophylaxis on specified days.
Extended NK1 antagonism coverage windows.
Combination regimen claims combining NK1 antagonists with 5-HT3 antagonists and corticosteroids in defined dosing schedules.

Design-around strategy for generic applicants

Carve out indications or shift regimen language.
Seek label alignment that avoids claim elements tied to dosing days, dosing sequence, or combination components.

How does NK1 antagonism compare with other antiemetic classes in patent posture?

Featured snippet answer: Compared with 5-HT3 antagonists and corticosteroids, NK1 antagonists tend to have narrower but more schedule-sensitive method-of-use and prodrug/formulation IP, which drives later-stage litigation around specific CINV regimens rather than broad compound freedom.

Competitive patent posture by class

5-HT3 antagonists: often face heavy generic penetration due to earlier expiries and more extensive commercial generic history.
NK1 antagonists: typically have fewer active competitors and more concentrated estates with targeted lifecycle protection around regimen schedules.
Corticosteroids: generics dominate; IP is not the key determinant in most markets.

What generic entry risks exist for NK1 receptor antagonists by product and presentation?

Featured snippet answer: Generic entry risk is highest where remaining patents are formulation or narrowly scoped method patents and where label carve-outs can be negotiated. Risk is lowest when remaining patents are core composition/prodrug claims or broad method-of-use claims tied to the full approved regimen.

Risk ranking framework

Low risk: core composition/prodrug patents + strong method-of-use coverage still active.
Medium risk: core expired, but formulation/product and schedule-specific method patents remain.
High risk: only narrow formulation patents left or when method-of-use claims are likely to be designed around or limited by label differences.

Biosimilar risk: is it relevant for NK1 antagonists?

Featured snippet answer: No. NK1 antagonists in this class are small molecules; biosimilar frameworks do not apply. The relevant competitive threats are generics, authorized generics, and line extensions rather than biosimilars.

Who are the key companies associated with NK1 antagonist products and challenges?

Featured snippet answer: Commercially, NK1 antagonists are held by originators that own core compound/prodrug and lifecycle IP. Generic entrants typically participate via US Paragraph IV challenges to listed Orange Book patents, followed by settlement-driven entry timing.

Company archetypes in the NK1 market

Originators: control core patents, prodrug IP, and life-cycle formulations.
Generic challengers: seek market entry by certifying patent invalidity/non-infringement.
Manufacturing and supply network players: matter for execution of stable IV product supply once patent barriers fall.

What licensing deals and authorized generic strategies influence the NK1 market?

Featured snippet answer: Licensing and authorized generic deals can accelerate revenue capture by settling around contested patents while preserving some exclusivity benefits through controlled launch timing and negotiated commercial terms.

How licensing typically changes leverage

Settlement reduces uncertainty and litigation cost.
Authorized generics can capture market share immediately after entry while keeping originator economics via revenue share or royalties.

FDA regulatory status: what pathways matter for NK1 generics?

Featured snippet answer: NK1 antagonists are typically pursued under Abbreviated New Drug Application (ANDA) routes for generics. The pathway hinges on Paragraph IV certifications against Orange Book-listed patents for the listed indication(s).

Key regulatory considerations

Generic label must generally align with reference listed drug (RLD) unless carving is needed to avoid method patents.
Bioequivalence requirements apply for oral forms; IV forms often require bridging strategies consistent with reference product specifications.

Key Takeaways

The NK1 receptor antagonist market is concentrated in CINV prophylaxis, where protocol embedding and combination regimens protect demand.
Patent estates are multi-layered: core compound/prodrug protection, then formulation and schedule-specific method-of-use coverage.
Generic entry risk is driven by the last unexpired, label-relevant US patents, not just core expiry dates.
Formulation and dosing regimen patents can extend effective exclusivity even after composition/prodrug patents lapse.
Litigation and settlement outcomes typically determine practical launch timing more than patent invalidation alone.

FAQs

1) What patents most often get challenged for NK1 antagonist CINV products in Paragraph IV filings?
Answer: Listed Orange Book method-of-use and drug product formulation patents mapped to label dosing schedules are the most frequently targeted layers once core substance patents lapse.

2) Can NK1 antagonist generics launch with a label carve-out to avoid method-of-use infringement?
Answer: Yes, carve-outs that change regimen language tied to claim elements can reduce infringement exposure, often forming the basis for settlement positioning.

3) Do IV NK1 antagonist prodrugs face different IP barriers than oral NK1 antagonists?
Answer: Yes. IV products tend to have heavier product and stability/formulation claim coverage tied to solution/infusion behavior.

4) How does last-to-expire patent selection affect settlement entry dates for NK1 antagonists?
Answer: Settlements usually anchor on the last unexpired US patent that remains relevant to the proposed generic label and market authorization.

5) Is there any biosimilar competition in the NK1 antagonist class?
Answer: No. These are small molecules; competition comes from generics and authorized generics.

References (APA)

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. (n.d.). Hatch-Waxman and Paragraph IV Abbreviated New Drug Applications: Overview materials and guidance. https://www.fda.gov/drugs/
United States Patent and Trademark Office. (n.d.). Patent assignment and publication search resources. https://www.uspto.gov/